Lyell Immunopharma, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Seely Lynn | President and CEO | Sale | 412 | $16.11 | $6,637 | 67,159 | Nov 10, 2025 |
| Bulis Veronica Sanchez | VP, Corporate Controller | Sale | 239 | $16.10 | $3,848 | 9,213 | Nov 10, 2025 |
| Lee Gary K. | Chief Scientific Officer | Sale | 138 | $16.16 | $2,230 | 15,366 | Nov 10, 2025 |
| Hill Stephen J. | Chief Operating Officer | Sale | 95 | $16.12 | $1,531 | 15,750 | Nov 10, 2025 |
| Hill Stephen J. | Chief Operating Officer | Award / Grant | 8,000 | — | — | 16,849 | Aug 21, 2025 |
| Lee Gary K. | Chief Scientific Officer | Award / Grant | 8,000 | — | — | 16,957 | Aug 21, 2025 |
| Seely Lynn | President and CEO | Sale | 7,257 | $10.54 | $76,489 | 67,571 | Aug 20, 2025 |
| Newton Charles W. | Chief Financial Officer | Sale | 1,453 | $10.54 | $15,315 | 15,306 | Aug 20, 2025 |
| Seely Lynn | President and CEO | Sale | 391 | $10.53 | $4,117 | 35,234 | Aug 12, 2025 |
| Lee Gary K. | Chief Scientific Officer | Sale | 131 | $10.53 | $1,379 | 9,093 | Aug 12, 2025 |
| Newton Charles W. | Chief Financial Officer | Sale | 131 | $10.53 | $1,379 | 8,895 | Aug 12, 2025 |
| Hill Stephen J. | Chief Operating Officer | Sale | 94 | $10.34 | $972 | 8,849 | Aug 11, 2025 |
| Shook David | Chief Medical Officer | Award / Grant | 21,900 | — | — | 21,900 | Jun 9, 2025 |
| BRAWLEY OTIS W | — | Purchase | 35,640 | $0.56 | $19,958 | 35,640 | Mar 31, 2025 |
| Ramachandra Sumant | — | Purchase | 200,000 | $0.58 | $116,000 | 200,000 | Mar 21, 2025 |
| Newton Charles W. | Chief Financial Officer | Purchase | 200,000 | $0.56 | $112,000 | 200,000 | Mar 17, 2025 |
| Klausner Richard | — | Purchase | 158,000 | $0.60 | $94,800 | 843,365 | Mar 14, 2025 |
| Seely Lynn | President and CEO | Purchase | 175,000 | $0.61 | $106,750 | 712,500 | Mar 14, 2025 |
| Lang Matthew | Chief Business Officer | Award / Grant | 112,500 | — | — | 162,500 | Feb 10, 2025 |
| Seely Lynn | President and CEO | Award / Grant | 337,500 | — | — | 537,500 | Feb 10, 2025 |
| Hill Stephen J. | Chief Operating Officer | Award / Grant | 112,500 | — | — | 172,899 | Feb 10, 2025 |
| Newton Charles W. | Chief Financial Officer | Award / Grant | 112,500 | — | — | 172,725 | Feb 10, 2025 |
| Lee Gary K. | Chief Scientific Officer | Award / Grant | 112,500 | — | — | 176,696 | Feb 10, 2025 |
| Lang Matthew | Chief Business Officer | Award / Grant | 50,000 | — | — | 50,000 | Feb 9, 2024 |
| Hill Stephen J. | Chief Operating Officer | Award / Grant | 40,000 | — | — | 48,928 | Feb 9, 2024 |
| Lee Gary K. | Chief Scientific Officer | Award / Grant | 40,000 | — | — | 52,700 | Feb 9, 2024 |
| Newton Charles W. | Chief Financial Officer | Award / Grant | 40,000 | — | — | 48,729 | Feb 9, 2024 |
| Seely Lynn | President and CEO | Award / Grant | 200,000 | — | — | 200,000 | Feb 9, 2024 |
| Klausner Richard | — | Sale | 58,020 | $2.28 | $132,286 | 930,880 | Aug 15, 2023 |
| Klausner Richard | — | Sale | 11,100 | $6.40 | $71,040 | 988,900 | Sep 23, 2022 |
| Bishop Hans Edgar | — | Option Exercise | 145,380 | $0.10 | $14,538 | 4,685,614 | Sep 8, 2022 |
| Bishop Hans Edgar | — | Option Exercise | 993,428 | $0.10 | $99,343 | 4,540,234 | Feb 23, 2022 |
| FRIEDMAN CATHY | — | Other | 218,722 | — | — | 236,370 | Dec 14, 2021 |
| FRIEDMAN CATHY | — | C | 3,765,842 | — | — | 3,765,842 | Jun 21, 2021 |
| Bishop Hans Edgar | — | C | 546,806 | — | — | 3,546,806 | Jun 21, 2021 |
| Klausner Richard | Executive Chairman | C | 3,765,842 | — | — | 3,765,842 | Jun 21, 2021 |
| NELSEN ROBERT | — | C | 18,206,358 | — | — | 18,206,358 | Jun 21, 2021 |
| ARCH Venture Fund IX, L.P. | — | C | 18,206,358 | — | — | 18,206,358 | Jun 21, 2021 |
| GLAXOSMITHKLINE PLC | — | C | 30,253,189 | — | — | 30,253,189 | Jun 21, 2021 |